CHMP positive for Roclanda for the reduction of elevated intraocular pressure with primary open-angle glaucoma or ocular hypertension- Aerie Pharma

Aerie Pharmaceuticals, Inc. has announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of the marketing authorisation application (MAA) for Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. The recommended indication is the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction. Roclanda is currently marketed as Rocklatan in the United States and is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or hypertension..